Bicycle Therapeutics

BCYC · NASDAQ

$3.60+$0.065 (+1.84%)TodayMarket closed · Oct 20, 7:38 PM ET

Prev close $3.54

Latest news

Press releaseJul 30, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Press releaseMay 21, 5:00 PM ETBusiness Wire
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Press releaseApr 30, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Press releaseApr 21, 10:31 AM ETBusiness Wire
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Press releaseApr 20, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Press releaseMar 18, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
Press releaseMar 17, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Press releaseFeb 3, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
NewsJan 12, 7:40 AM ET
Bicycle Therapeutics Outlines 2026 Strategy With Duravelo-2 Regulatory Update Expected In 1Q 2026, Radiopharmaceutical Data In 2026, And Runway Into 2028
Press releaseJan 12, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
Press releaseDec 16, 1:00 AM ETBusiness Wire
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
Press releaseDec 11, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Press releaseNov 20, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Press releaseNov 12, 4:05 PM ETBusiness Wire
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Press releaseOct 30, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
Press releaseSep 8, 4:05 PM ETBusiness Wire
Bicycle Therapeutics Strengthens Board of Directors with New Appointments
NewsAug 12, 3:00 PM ET
4 Analysts Assess Bicycle Therapeutics: What You Need To Know
Press releaseAug 8, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Press releaseJul 31, 7:00 AM ETPRNewswire
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
NewsJul 17, 6:01 PM ET
Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews
Press releaseJul 2, 4:05 PM ETBusiness Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 3, 4:05 PM ETBusiness Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 22, 5:05 PM ETBusiness Wire
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
Press releaseMay 5, 4:05 PM ETBusiness Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMay 2, 10:00 AM ET
A Glimpse Into The Expert Outlook On Bicycle Therapeutics Through 7 Analysts
Press releaseMay 1, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
Press releaseApr 29, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
NewsApr 9, 4:01 PM ET
Analyst Expectations For Bicycle Therapeutics's Future
Press releaseApr 2, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseApr 1, 7:00 AM ETBusiness Wire
Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
NewsFeb 26, 3:01 PM ET
Deep Dive Into Bicycle Therapeutics Stock: Analyst Perspectives (9 Ratings)
NewsJan 13, 5:00 PM ET
Forecasting The Future: 11 Analyst Projections For Bicycle Therapeutics
NewsDec 16, 1:00 PM ET
Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views
Press releaseOct 31, 7:00 AM ETBusiness Wire
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
NewsOct 24, 8:00 AM ET
Navigating 11 Analyst Ratings For Bicycle Therapeutics
NewsSep 6, 1:37 PM ETVandana Singh
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
NewsSep 6, 8:01 AM ET
In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics
NewsAug 7, 5:00 PM ET
The Latest Analyst Ratings For Bicycle Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

Bicycle Therapeutics Outlines 2026 Strategy With Duravelo-2 Regulatory Update Expected In 1Q 2026, Radiopharmaceutical Data In 2026, And Runway Into 2028

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Bicycle Therapeutics Strengthens Board of Directors with New Appointments

4 Analysts Assess Bicycle Therapeutics: What You Need To Know

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

A Glimpse Into The Expert Outlook On Bicycle Therapeutics Through 7 Analysts

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Analyst Expectations For Bicycle Therapeutics's Future

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Deep Dive Into Bicycle Therapeutics Stock: Analyst Perspectives (9 Ratings)

Forecasting The Future: 11 Analyst Projections For Bicycle Therapeutics

Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Navigating 11 Analyst Ratings For Bicycle Therapeutics

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics

The Latest Analyst Ratings For Bicycle Therapeutics